Chronic Liver Disease Clinical Trial
Official title:
Multi-Center, Randomized, Control, Phase IV Trial to Compare the Efficacy & Safety of Ursoplus® Capsules (UDCA 250mg & Silymarin 140mg) Versus UDCA Alone Versus Placebo Among Compensated Chronic Liver Diseased Patients
This study aims to compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients
Research Question: Compare the efficacy & safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA alone versus Placebo among Compensated chronic liver diseased patients Primary Objective: To assess the efficacy of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250mg alone and versus Placebo in the reduction of total serum bilirubin, Direct serum bilirubin and elevated liver Enzymes from baseline to End of Treatment (EOT) Secondary Objectives: - To assess the efficacy of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo in reducing the degree of steatosis as measured by Vibration-controlled transient elastography with Controlled Attenuation Parameter (CAP) - To assess the safety of Ursoplus® capsules (UDCA 250mg & Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo among compensated Chronic Liver Diseased Patients - To describe improvement in quality of life for patients after treatment A study population of 297 patients suffering from compensated chronic Liver Disease, who will be randomized according to Vibration-controlled transient elastography in screening visit into 2 groups: - Group 1: with non-cirrhosis, F0, F1 and F2. - Group 2: with advanced fibrosis and cirrhosis, F3 and F4. Each group will receive either Ursoplus® capsules (UDCA 250mg & Silymarin 140mg), or UDCA alone or Placebo, through Stratified random sampling. Duration for enrollment: 6 months Total duration of the study/subject will be approximately: 6 months for treatment and follow-up visits including the screening visit Subjects will be enrolled for a duration of 6 months including the screening visit - Screening visit 1 (Treatment initiation) - Visit 2: after 1st month, follow-up 1 - Visit 3: after 2nd month, follow-up 2 - Visit 4: after 3rd month, follow-up 3 - Visit 5: after 4th month, follow-up 4 - Visit 6: after 5th month, follow-up 5 - End of Study visit, after 6th month of treatment, follow-up 6 ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03704792 -
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference
|
N/A | |
| Terminated |
NCT02949375 -
Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
|
Phase 2 | |
| Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
| Completed |
NCT00756171 -
Colesevelam Versus Placebo in Cholestatic Pruritus
|
Phase 2/Phase 3 | |
| Completed |
NCT01195181 -
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.
|
Phase 4 | |
| Completed |
NCT05044663 -
Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.
|
||
| Recruiting |
NCT04588077 -
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
|
Phase 4 | |
| Recruiting |
NCT04802954 -
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients
|
N/A | |
| Recruiting |
NCT04622449 -
Etiopathogenesis of Anemia in Chronic Liver Disease
|
||
| Enrolling by invitation |
NCT05836246 -
The Development of Quantitative Ultrasound Imaging Software Platform
|
||
| Completed |
NCT03087344 -
Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis
|
N/A | |
| Completed |
NCT04751045 -
Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies
|
N/A | |
| Not yet recruiting |
NCT04526548 -
A Diagnostic Study on Patients With Drug-induced Liver Injury
|
||
| Withdrawn |
NCT02899325 -
FDGal PET/CT to Detect Hepatocellular Carcinoma
|
||
| Terminated |
NCT02530567 -
Non-invasive Evaluation of Portal Pressure by MRI
|
N/A | |
| Suspended |
NCT02650011 -
Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease
|
||
| Completed |
NCT01851252 -
MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy
|
Phase 1 | |
| Terminated |
NCT01756690 -
Predicting Lung Injury From Transfusion in Patients With Liver Disease
|
N/A | |
| Completed |
NCT01600105 -
Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)
|
Phase 4 | |
| Completed |
NCT01008293 -
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
|
Phase 2/Phase 3 |